Valdoxan

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Agomelatine

Available from:

Les Laboratoires Servier

ATC code:

N06AX22

INN (International Name):

Agomelatine

Therapeutic group:

Psychoanaleptics,

Therapeutic area:

Disturb depressiv, Maġġur

Therapeutic indications:

Trattament ta 'episodji depressivi maġġuri fl-adulti.

Product summary:

Revision: 24

Authorization status:

Awtorizzat

Authorization date:

2009-02-19

Patient Information leaflet

                                22
B. FULJETT TA’ TAGĦRIF
23
FULJETT TA' TAGĦRIF: INFORMAZZJONI GĦALL-PAZJENT
VALDOXAN 25 MG PILLOLI MIKSIJA B’RITA
agomelatine
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI IMPORTANTI
GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’ tagħmlilhom il-
ħsara anke jekk għandhom l-istess sinjali ta’ mard bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Valdoxan u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Valdoxan
3.
Kif għandek tieħu Valdoxan
4.
Effetti sekondarji possibbli
5.
Kif taħżen Valdoxan
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X'INHU VALDOXAN U GĦALXIEX JINTUŻA
Valdoxan fih is-sustanza attiva agomelatine. Din t-appartjeni taħt
il-grupp ta’ mediċini li jissejħu
antidippressanti. Int ġejt mogħti Valdoxan biex tikkura
d-dipressjoni tiegħek.
Valdoxan jintuża fl-adulti.
Id-dipressjoni hija taħwid kontinwu tal-burdata li tinterferixxi
mal-ħajja ta’ kuljum. Is-sintomi tad-
dipressjoni jvarjaw minn persuna għall-oħra, iżda ħafna drabi
jinkludu dwejjaq kbar, sens ta’ nuqqas ta’
valur, telf tal-interess f’attivitajiet favoriti, disturbi fl-irqad,
sens li tħossok sejjer lura, sens ta’ anzjetà, bdil
fil-piż.
Il-benefiċċji mistennija ta’ Valdoxan għandhom inaqqsu u
gradwalment ineħħu s-sintomi relatati mad-
dipressjoni tiegħek.
2.
X'GĦANDEK TKUN TAF QABEL MA TIEĦU VALDOXAN
TIĦUX VALDOXAN
-
jekk inti allerġiku għal agomelatine jew għal xi sustanza oħra
ta’ din il-mediċina (imniżżla fis-sezzjoni
6)
-
JEKK IL-FWIED TIEGĦEK MA JAĦDIMX KIF SUPPOST (INDEBOLIMENT EPATIKU).
jekk qed tieħu fluvoxamine (mediċin
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Valdoxan 25 mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
_ _
Kull pillola miksija b’rita fiha 25 mg t’agomelatine.
Eċċipjent b’effett magħruf
Kull pillola miksija b’rita fiha 61.8 mg lactose (bħala
monohydrate).
Għal-lista sħiħa ta' eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita (pillola).
Pillola rettangolari oranġjo fl-isfar, twila 9.5 mm, wiesgħa 5.1 mm
miksija b’rita bil-logo tal-kumpanija
mnaqqax bil-blu fuq naħa minnhom.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Valdoxan huwa indikat għall-kura ta’ episodji dipressivi maġġuri
f’adulti.
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
Id-doża rrakkomandata hija ta’ 25 mg darba kuljum meħuda
mill-ħalq qabel l-irqad.
Wara ġimagħtejn ta’ kura, jekk is-sintomi ma jmorrux
għall-aħjar, id-doża tista’ tiżdied għal 50 mg darba
kuljum, i.e. żewġ pilloli ta’ 25 mg, meħudin flimkien qabel
l-irqad.
Id-deċiżjoni li tiżdied id-doża trid tkun ibbilanċjata ma’
riskju akbar ta’ żieda fit-transaminases. Kwalunkwe
żieda fid-doża għal 50 mg għandha ssir fuq bażi
tal-benefiċċju/riskju għall-pazjent individwali u b’rispett
strett tal-monitoraġġ tat-Testijiet tal-Funzjoni tal-Fwied).
Testijiet tal-funzjoni tal-fwied għandhom isiru fil-pazjenti kollha
qabel il-bidu tal-kura. Il-kura ma għandhiex
tinbeda jekk it-transaminażi taqbeż 3 darbiet il-limitu ta’ fuq
tan-normal (ara sezzjonijiet 4.3 u 4.4).
Matul il-kura, it-transaminażi għandha tiġi mmonitorjata
perjodikament wara madwar tliet ġimgħat, sitt
ġimgħat (tmiem tal-fażi akuta), tnax-il ġimgħa u erbgħa u
għoxrin ġimgħa (tmiem tal-fażi ta’ manteniment) u
wara dan meta klinikament indikat (ara wkoll sezzjoni 4.4). Il-kura
għandha titwaqqaf jekk it-transaminażi
taqbeż 3 darbiet il-limitu ta’ fuq tan-normal (ara sezzjonijiet 4.3
u 4.4).
Meta jiżdied id-dożaġġ, it-
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 25-11-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 25-11-2021
Public Assessment Report Public Assessment Report Bulgarian 19-01-2017
Patient Information leaflet Patient Information leaflet Spanish 25-11-2021
Public Assessment Report Public Assessment Report Spanish 19-01-2017
Patient Information leaflet Patient Information leaflet Czech 25-11-2021
Public Assessment Report Public Assessment Report Czech 19-01-2017
Patient Information leaflet Patient Information leaflet Danish 25-11-2021
Public Assessment Report Public Assessment Report Danish 19-01-2017
Patient Information leaflet Patient Information leaflet German 25-11-2021
Public Assessment Report Public Assessment Report German 19-01-2017
Patient Information leaflet Patient Information leaflet Estonian 25-11-2021
Public Assessment Report Public Assessment Report Estonian 19-01-2017
Patient Information leaflet Patient Information leaflet Greek 25-11-2021
Public Assessment Report Public Assessment Report Greek 19-01-2017
Patient Information leaflet Patient Information leaflet English 25-11-2021
Public Assessment Report Public Assessment Report English 19-01-2017
Patient Information leaflet Patient Information leaflet French 25-11-2021
Public Assessment Report Public Assessment Report French 19-01-2017
Patient Information leaflet Patient Information leaflet Italian 25-11-2021
Public Assessment Report Public Assessment Report Italian 19-01-2017
Patient Information leaflet Patient Information leaflet Latvian 25-11-2021
Public Assessment Report Public Assessment Report Latvian 19-01-2017
Patient Information leaflet Patient Information leaflet Lithuanian 25-11-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 25-11-2021
Public Assessment Report Public Assessment Report Lithuanian 19-01-2017
Patient Information leaflet Patient Information leaflet Hungarian 25-11-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 25-11-2021
Public Assessment Report Public Assessment Report Hungarian 19-01-2017
Patient Information leaflet Patient Information leaflet Dutch 25-11-2021
Public Assessment Report Public Assessment Report Dutch 19-01-2017
Patient Information leaflet Patient Information leaflet Polish 25-11-2021
Public Assessment Report Public Assessment Report Polish 19-01-2017
Patient Information leaflet Patient Information leaflet Portuguese 25-11-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 25-11-2021
Public Assessment Report Public Assessment Report Portuguese 19-01-2017
Patient Information leaflet Patient Information leaflet Romanian 25-11-2021
Public Assessment Report Public Assessment Report Romanian 19-01-2017
Patient Information leaflet Patient Information leaflet Slovak 25-11-2021
Public Assessment Report Public Assessment Report Slovak 19-01-2017
Patient Information leaflet Patient Information leaflet Slovenian 25-11-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 25-11-2021
Public Assessment Report Public Assessment Report Slovenian 19-01-2017
Patient Information leaflet Patient Information leaflet Finnish 25-11-2021
Public Assessment Report Public Assessment Report Finnish 19-01-2017
Patient Information leaflet Patient Information leaflet Swedish 25-11-2021
Public Assessment Report Public Assessment Report Swedish 19-01-2017
Patient Information leaflet Patient Information leaflet Norwegian 25-11-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 25-11-2021
Patient Information leaflet Patient Information leaflet Icelandic 25-11-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 25-11-2021
Patient Information leaflet Patient Information leaflet Croatian 25-11-2021
Public Assessment Report Public Assessment Report Croatian 19-01-2017

Search alerts related to this product

View documents history